{"id":52058,"date":"2022-12-15T22:02:57","date_gmt":"2022-12-15T21:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/"},"modified":"2022-12-15T22:02:57","modified_gmt":"2022-12-15T21:02:57","slug":"angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/","title":{"rendered":"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023"},"content":{"rendered":"
\n

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open on Thursday, January 5, 2023. The Company\u2019s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.\n<\/p>\n

<\/a><\/p>\n

\nTo participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13734978.\n<\/p>\n

\nThis conference call will also be webcast and can be accessed from the \u201cInvestors\u201d section of the AngioDynamics website at www.angiodynamics.com<\/a>. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.\n<\/p>\n

\nA recording of the call will also be available from 11:00 a.m. ET on Thursday, January 5, 2023, until 11:59 p.m. ET on Thursday, January 12, 2023. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13734978.\n<\/p>\n

\nAbout AngioDynamics, Inc.<\/b>\n<\/p>\n

\nAngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients.\n<\/p>\n

\nThe Company\u2019s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
AngioDynamics, Inc.
\n
Stephen Trowbridge, Executive Vice President & CFO
\n
(518) 795-1408\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52058","6":"format-standard","7":"category-industry"},"yoast_head":"\nAngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-15T21:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221215006035\/en\/664620\/21\/ANGO_-_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023\",\"datePublished\":\"2022-12-15T21:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/\"},\"wordCount\":275,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215006035\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/\",\"name\":\"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215006035\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\",\"datePublished\":\"2022-12-15T21:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215006035\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215006035\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/","og_locale":"en_US","og_type":"article","og_title":"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023 - Pharma Trend","og_description":"LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-15T21:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221215006035\/en\/664620\/21\/ANGO_-_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023","datePublished":"2022-12-15T21:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/"},"wordCount":275,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221215006035\/en\/664620\/21\/ANGO_-_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/","url":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/","name":"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221215006035\/en\/664620\/21\/ANGO_-_Logo.jpg","datePublished":"2022-12-15T21:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221215006035\/en\/664620\/21\/ANGO_-_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221215006035\/en\/664620\/21\/ANGO_-_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-second-quarter-financial-results-on-january-5-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52058"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52058\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}